Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Recruiting · NCT03297775 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Colorado, Denver
View the official record on ClinicalTrials.gov →What this trial is about
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.
Who can take part
Age range
45 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- ≥ 45years old
- Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria
Exclusion criteria
- Inability to give informed consent
- Pregnant women
- History of interstitial lung disease
- Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.
- Subjects over the age of 90 years old or less than 45 years old
Where it is running
1 location listed across 1 US state.
- University of Colorado - Anschutz Medical Campus - Aurora, Colorado, United States